PCSA Live signals | Maximize Profits with Getagraph.com

BUY 105390 min ago

@ $2.43

Issued: 12 Feb 2024 @ 15:26

Return: 0.00%

Previous signal: Feb 6 - 14:26

Previous signal: Sell

Return: 0.00 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States...

Stats
Today's Volume	76.90M
Average Volume	433 822
Market Cap	6.94M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.290
ATR14	$0.0410 (1.70%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-01	Young David	Buy	1 675	Common Stock
2024-01-01	Young David	Sell	518	Common Stock
2024-01-01	Young David	Sell	1 675	Restricted Stock Units
2024-01-01	Stanker James H	Sell	1 675	Restricted Stock Units
2024-01-01	Stanker James H	Buy	1 675	Common Stock

INSIDER POWER
80.26
Last 99 transactions
Buy: 3 005 145 \| Sell: 402 801

Volume Correlation

Long: 0.36 (neutral)

Short: -0.41 (neutral)

Signal:(48.485) Neutral

Processa Pharmaceuticals, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Processa Pharmaceuticals, Correlation - Currency/Commodity

0.44
( neutral )

0.48
( neutral )

0.00
( neutral )

0.46
( neutral )

-0.42
( neutral )

0.05
( neutral )

Processa Pharmaceuticals, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-222.00 (0.00 %)
EPS:	$-8.48

Q4	2023
Revenue:	$0
Gross Profit:	$-140.00 (0.00 %)
EPS:	$-1.870

Q3	2023
Revenue:	$0
Gross Profit:	$-2.17M (0.00 %)
EPS:	$-1.540

Q2	2023
Revenue:	$0
Gross Profit:	$-2.71M (0.00 %)
EPS:	$-1.940

Financial Reports:

No articles found.

Processa Pharmaceuticals,

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.